Innate Pharma Stock Price on December 4, 2024
| IPHA Stock | USD 1.62 0.18 10.00% |
Below is the normalized historical share price chart for Innate Pharma extending back to October 17, 2019. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Innate Pharma stands at 1.62, as last reported on the 11th of December 2024, with the highest price reaching 1.62 and the lowest price hitting 1.62 during the day.
If you're considering investing in Innate Stock, it is important to understand the factors that can impact its price. Innate Pharma holds Efficiency (Sharpe) Ratio of -0.0542, which attests that the entity had a -0.0542% return per unit of risk over the last 3 months. Innate Pharma exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Innate Pharma's Market Risk Adjusted Performance of (0.13), risk adjusted performance of (0.01), and Standard Deviation of 6.22 to validate the risk estimate we provide.
At present, Innate Pharma's Total Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Liabilities And Stockholders Equity is expected to grow to about 188 M, whereas Common Stock Total Equity is forecasted to decline to about 2.5 M. . The current year's Price Earnings To Growth Ratio is expected to grow to 0.34, whereas Price To Sales Ratio is forecasted to decline to 3.86. Innate Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 17th of October 2019 | 200 Day MA 2.2479 | 50 Day MA 1.8263 | Beta 0.868 |
Innate |
Sharpe Ratio = -0.0542
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IPHA |
Estimated Market Risk
| 6.39 actual daily | 56 56% of assets are less volatile |
Expected Return
| -0.35 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Innate Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Innate Pharma by adding Innate Pharma to a well-diversified portfolio.
Price Book 4.7943 | Enterprise Value Ebitda (6.94) | Price Sales 4.3125 | Shares Float 31.6 M | Wall Street Target Price 7.412 |
Related Headline
Shattuck Labs Headline on 4th of December 2024
Disposition of 1026888 shares by Redmile Group, Llc of Shatt... by Redmile Group, Llc
Filed transaction by Shattuck Labs Director, 10 Percent Owner: . Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Innate Pharma Valuation on December 4, 2024
It is possible to determine the worth of Innate Pharma on a given historical date. On December 4, 2024 Innate was worth 1.51 at the beginning of the trading date compared to the closed value of 1.45. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Innate Pharma stock. Still, in general, we apply an absolute valuation method to find Innate Pharma's value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Innate Pharma where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Innate Pharma's related companies.
| Open | High | Low | Close | Volume | |
| 1.51 | 1.51 | 1.51 | 1.51 | 512.00 | |
12/04/2024 | 1.51 | 1.51 | 1.41 | 1.45 | 14,900 |
| 1.46 | 1.46 | 1.43 | 1.45 | 21,634 |
| Backtest Innate Pharma | | | Innate Pharma History | | | Innate Pharma Valuation | Previous | Next |
Innate Pharma Trading Date Momentum on December 4, 2024
| On December 05 2024 Innate Pharma was traded for 1.45 at the closing time. The top price for the day was 1.46 and the lowest listed price was 1.43 . The trading volume for the day was 21.6 K. The trading history from December 5, 2024 did not cause price change. The trading delta at closing time against the current closing price is 24.14% . |
Innate Pharma Fundamentals Correlations and Trends
By evaluating Innate Pharma's financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Innate Pharma's main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Innate financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Innate Pharma Stock history
Innate Pharma investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Innate is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Innate Pharma will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Innate Pharma stock prices may prove useful in developing a viable investing in Innate Pharma
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 80.5 M | 53.1 M | |
| Net Loss | -52.3 M | -49.7 M |
Innate Pharma Quarterly Net Working Capital |
|
Innate Pharma Stock Technical Analysis
Innate Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Innate Pharma Period Price Range
Low | December 11, 2024
| High |
0.00 | 0.00 |
Innate Pharma cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Innate Pharma December 11, 2024 Market Strength
Market strength indicators help investors to evaluate how Innate Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Innate Pharma shares will generate the highest return on investment. By undertsting and applying Innate Pharma stock market strength indicators, traders can identify Innate Pharma entry and exit signals to maximize returns
Innate Pharma Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Innate Pharma's price direction in advance. Along with the technical and fundamental analysis of Innate Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Innate to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.01) | |||
| Jensen Alpha | (0.30) | |||
| Total Risk Alpha | (1.15) | |||
| Treynor Ratio | (0.14) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Complementary Tools for Innate Stock analysis
When running Innate Pharma's price analysis, check to measure Innate Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innate Pharma is operating at the current time. Most of Innate Pharma's value examination focuses on studying past and present price action to predict the probability of Innate Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innate Pharma's price. Additionally, you may evaluate how the addition of Innate Pharma to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |